Experts Rebutted In Pfizer's Celebrex Case

Law360, New York (July 23, 2007, 12:00 AM EDT) -- A dispute has erupted over proposed testimony in the product liability litigation over pharmaceutical giant Pfizer Inc.'s anti-inflammatory drug Celebrex, with both sides calling on a judge to bar the experts' opinions.

Pfizer wants the California district judge to strike testimony by plaintiffs' experts alleging a heightened risk of heart attacks and strokes with Celebrex use. The drug maker claims the opinions, proffered by experts designated by the plaintiffs' steering committee, are unreliable, irrelevant and inadmissible, relying heavily on questionable scientific studies and a “speculative and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.